n n n ‘. concat(e. i18n. t(“search. voice. recognition_retry”),’n
Virtual Care Suite (VCS) is now available for licensing in the U. S. The U. S. Food and Drug Administration is a non-profit organization for providers who provide GLP-1 and other drug treatments for obesity, bariatric surgery, and weight-loss devices.
The launch of the product in the U. S. The U. S. Vaccine Survey will begin at the Conference on Obesity Medicine in Denver on April 25.
NATICK, Mass. , April 4, 2024–(BUSINESS WIRE)–Allurion Technologies, Inc. (NYSE: ALUR), a company committed to ending obesity, announced the advertising availability of its complete virtual care package (VCS) in the United States.
Already used by thousands of providers in more than 50 countries, VCS is a dynamic weight loss management package powered by synthetic intelligence (AI) that aggregates remote patient monitoring, telehealth, and care team collaboration, all under one virtual umbrella, designed to maximize patient benefit. . results and satisfaction. In 2023, Allurion added the VCS Coach Iris, an AI-powered weight loss coach that works 24/7, enabling automated conversational coaching and a more personalized habit replacement program tailored to patients’ needs.
“After witnessing the profound impact of our generation on a global scale, we are thrilled to launch the VCS in the U. S. U. S. Our team is incredibly excited to provide clinics across the U. S. with the opportunity to provide clinics across the U. S. with the opportunity to provide clinics across the U. S. with the helpU. S. Department of Homeland Security (CDC) has developed virtual responses to help them dramatically improve clinical outcomes and the patient experience. “Our studies indicate that VCS has already improved patient outcomes,” said Brian Conyer, vice president of virtual health. , commitment and satisfaction. Clinics with the highest use of VCS to achieve an additional 11%1 weight loss, with 16% more patients achieving their goals1 and a 17% increase in Net Promoter Score. (NPS) 2.
The VCS will be introduced for the first time in the U. S. The U. S. Department of Homeland Security will host the U. S. Centers for Disease Control and Prevention at the Obesity Medicine Conference in Denver on April 25, where providers will have the opportunity to request individual appointments to be informed about the solution. As a component of the launch, Allurion will also introduce a new edition of Allurion Insights, the web-based dashboard that vendors use to navigate VCS.
What’s new in Allurion Insights includes:
Responsive design similar to a mobile app: for providers and care groups in the pass who can stay in communication with their patients on their cell phones.
More Effective Navigation: Carefully organized through user activities, the updated browsing experience is designed to create smoother access to a variety of other streams of knowledge for each patient.
Multitasking: For busy providers, multitask to document a clinical note or start a video visit while seamlessly viewing other patients’ information.
“As the use of anti-obesity drugs increases in the U. S. , the U. S. is growing in the U. S. In the U. S. , providers face the challenge of providing close follow-up and training on large-scale lifestyle modifications,” said Shantanu Gaur, Founder and CEO. “We’re excited to make VCS” obtainable in the U. S. It can become an integral component of practices that provide weight loss treatments of any kind. “
Sources: 1. Allurion PEX Report, March 2023; 2. Allurion Inside Sales Excellence Analysis, Fourth Quarter 2023
About Allurion
Allurion is committed to ending obesity. The Allurion Program is a weight loss platform that includes the Allurion Gastric Balloon, the first and only swallowable, procedure-free intragastric balloon for weight loss, and provides access to the Allurion Virtual Care Suite, adding the Allurion consumer cellular app, Allurion. Insights for healthcare providers, with the Coach Iris AI platform and connected Allurion scale. The Allurion Virtual Care Suite is also available to providers separately from the Allurion program to help them personalize, monitor, and manage the weight loss cure for patients. regardless of your treatment plan: gastric balloon, surgical, medical, or nutritional. The Allurion gastric balloon is an experimental device in the United States.
To learn more about Allurion and Allurion Virtual Care Suite, visit www. allurion. com
Allurion is a trademark of Allurion Technologies, Inc. in the U. S. In the U. S. and internationally.
Forward-Looking Statements
This press release may include certain forward-looking statements within the meaning of U. S. federal and state securities laws. These forward-looking statements are sometimes referred to by the words “believe,” “project,” “expect,” “anticipate. ” , “estimate”, “intend”, “strategy”, “long-term”, “opportunity”, “matrix” plan. “, “possibly”, “will deserve”, “will be”, “will be”, “will continue”, “will most likely result” and similar expressions and come with statements relating to Allurion’s expectations and acceptance of the market position. Virtual Care Suite and the Allurion program in general, the ability of Allurion to scale its business and, in particular, for VCS, and the ability of VCS to improve clinical and patient outcomes. Are predictions, projections and other statements about events long-term that reflect existing ideals and assumptions of Allurion control based on data that already exists and are therefore subject to threats and insecurities. Many points may also cause actual long-term effects or progress to differ materially from the forward-looking statements involved in this release, including, among others, (i) Allurion’s ability to discharge and maintain regulatory approvals and effectively commercialize the Allurion Program, adding the Allurion balloon and the VCS, (ii) the timing and effects of our studies and clinical trials, (iii) developments in the market positions in which Allurion is active. competition, (iv) Allurion’s ability to protect its intellectual assets, (v) the effect of the COVID-19 pandemic, the war between Russia and Ukraine and the confrontation between Israel and Hamas on Allurion’s activities, (vi) Allurion’s expectations related to its market position opportunities, including those of the VCS platform, and (vii) the threat of economic downturns and a changing regulatory landscape in the highly competitive industry in which Allurion operates. The above list of points is not exhaustive. The above points and other threats and uncertainties described in the “Risk Factors” segment of Allurion’s Annual Report on Form 10-K filed on March 26, 2024 and in other documents filed with Allurion deserve careful consideration. from time to time with American Values. and Foreign Exchange Commission. These documents identify and address other vital threats and insecurities that may also cause actual events and effects to differ materially from those involved in the forward-looking statements. Forward-looking statements speak only as of the date on which they are made. Readers are cautioned not to place undue reliance on any forward-looking statements, and Allurion assumes no legal liability and does not intend to update or revise any forward-looking statements, whether as a result of new data, long-term events or otherwise. . Allurion makes no guarantee that it will meet your expectations.
See the edition in businesswire. com: https://www. businesswire. com/news/home/20240404646972/en/
Contactos
Worldwide Media: Cédric DamourPR Manager 33 7 21 02 20cdamour@allurion. com
Investors Mike Cavanaugh, Investor RelationsICR Westwicke(617) 877-9641mike. cavanaugh@westwicke. com